These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30166022)

  • 1. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 2. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
    Khunger M; Velcheti V
    J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
    [No Abstract]   [Full Text] [Related]  

  • 4. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
    Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
    Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.
    Gokozan HN; Friedman JD; Schmaier AH; Downes KA; Farah LA; Reeves HM
    Clin Lung Cancer; 2019 Sep; 20(5):e560-e563. PubMed ID: 31311716
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
    Wu L; Yu Y; Zhou J; Wang X; Li J; Wang Y
    Immunotherapy; 2020 Sep; 12(13):957-964. PubMed ID: 32686549
    [No Abstract]   [Full Text] [Related]  

  • 8. [A Case of Myocardial and Cutaneous Metastases of Squamous Cell Lung Cancer Post Left Pneumonectomy and Radical Surgery for Cutaneous Metastasis during Nivolumab Therapy].
    Watanabe I; Kanauchi N; Watanabe H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1441-1444. PubMed ID: 30382041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
    Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
    J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report.
    Kono K; Nakashima K; Tsubata Y; Amano Y; Kawakado K; Yanagawa T; Isobe T
    Thorac Cancer; 2024 Aug; 15(22):1714-1717. PubMed ID: 38956899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Basak EA; Koolen SLW; Hurkmans DP; Schreurs MWJ; Bins S; Oomen-de Hoop E; Wijkhuijs AJM; Besten ID; Sleijfer S; Debets R; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ
    Eur J Cancer; 2019 Mar; 109():12-20. PubMed ID: 30654225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    Komatsu T; Nakamura K; Kawase A
    J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged response after the discontinuation of nivolumab after resistance to gefitinib.
    Sasatani Y; Okauchi S; Ohara G; Kagohashi K; Satoh H
    Clin Respir J; 2019 Oct; 13(10):657-658. PubMed ID: 31343829
    [No Abstract]   [Full Text] [Related]  

  • 16. Nivolumab improves survival for patients with advanced lung cancer.
    Printz C
    Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
    Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
    Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
    Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
    Davis A; Mahar A; Wong K; Barnet M; Kao S
    Clin Lung Cancer; 2021 Sep; 22(5):e665-e667. PubMed ID: 33349572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.